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Purpose or Objective: Pediatric cancer treatment, including 
radiotherapy (RT) achieves high cure rates, but can cause 
late health problems. We aim to describe temporal trends of 
pediatric RT use in the Netherlands based on treatment 
experience in the DCOG-LATER cohort of five-yr childhood 
cancer survivors (CCS). 
 
Material and Methods: The Dutch Childhood Oncology Group 
– Late effects after childhood cancer (DCOG-LATER) is a 
collaborative effort of all 7 academic paediatric 
oncology/hematology centres in the Netherlands for optimal 
patient care and research. The DCOG-LATER cohort includes 
6168 five-yr CCS diagnosed 1963-2001 prior to age 18 yrs. 
Most children were treated according to (inter) national 
study protocols. Trained data-managers obtained individual 
medical file information on prior cancer diagnosis and 
treatment including prescribed RT dose, field(s), 
fractionation schedule, machine and RT technique from data 
were coded and stored in a web-based database using study 
coding manuals. Here we summarize trends in RT use by 
calendar period (1963-1979 vs 1980-2001) and diagnosis 
group. 
 
Results: In all, 2426 (39%) CCS received external beam RT 
(EBRT) for a primary tumor or recurrence, most often 
photons, or, <1989, Cobalt-60. Use of orthovoltage and 
electrons was limited. Brachytherapy (2%) and radio isotopes 
(2%) were given, mainly during 1990-2001. RT use decreased 
substantially for all cancer types; most dramatic changes 
were seen among CCS of acute lymphoblastic leukemia, Non-
Hodgkin lymphoma, neuroblastoma, and nephroblastoma, for 
whom RT-use declined from 92%, 79%, 59% and 76% (1963-
1979), to 15%, 8%, 8%, and 27% (1990-2001), respectively, but 
also for bone tumors (75%-32%), retinoblastoma (57%-16%), 
and CNS tumors (82%-47%). Modest declines were seen for 
CCS of Hodgkin lymphoma (74%-50%), soft tissue sarcomas 
(57%-36%), and germ-cell tumors (43%-26%). Among 2094 
leukemia survivors, 773 had any RT, directed to the cranium 
(56%), total body (22%), cranio-spinal axis (12%), and testes 
(4%). Formal trend analyses by childhood cancer type, body 
compartment, and RT dose will be presented. 
 
Conclusion: The use of RT declined over time for all 
pediatric cancer types, likely related to improved diagnostic 
techniques (CT/MRI/pathology) and the introduction of 
multimodal chemotherapy and enhanced surgical techniques. 
Temporal changes in treatment exposures document the 
magnitude of changes, illustrate the heterogeneity of 
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Purpose or Objective: To verify the adequacy of dose 
volume constraints in stereotactic radiotherapy and 
radiosurgery of abdominal area considering that dose 
constraints reported in literature are not still validated. This 
study is based on toxicity recorded in organs at risk (OARs) of 
patients enrolled in dose-escalation trials and treated in Our 
Institution. 
 
Material and Methods: Treatment plans of 51 patients (Table 
1) who underwent SBRT (30 patients) or SBRS (21 patients) on 
abdominal neoplasms from March 2007 to May 2014 were 
retrospectively evaluated. All patients were treated using V-
MAT technique. SBRT treatment was delivered in 25-40 Gy in 
5 fractions, and 16-30 Gy in single fraction in SBRS 
treatment. Small intestine and duodenum were the main 
OARs whose irradiation was virtually limited to 30 Gy in SBRT 
treatments and 12 Gy in SBRS treatments. Dosimetric data 
were compared with clinical results in terms of early and late 
toxicity. 




Results: SBRT treatment: maximum small bowel and 
duodenum dose-volume constraints were exceeded in 5/30 
(16.7%) and 2/30 (6.7%), respectively. Dose to OARs was: 
small bowel: Dmax 31.5-40.5 Gy, V30 0.2-13.4 cc; duodenum: 
Dmax 35.7-36.6 Gy, V30 2.1-3.7 cc. 
SBRS treatment: maximum small bowel and duodenum dose-
volume constraints were exceeded in 2/21 patients (9.5%) 
and 1/21 patient (4.7%), respectively. Dose to OARs was: 
small bowel: Dmax 15.6-16.3 Gy, V12 1.7-8.5 cc; duodenum 
Dmax 16.0 Gy, V12 0.1 cc. 
With a median follow up of 24 months after SBRT and 18 
months after SBRS, no early or late severe toxicity was 
observed in patients in whom constraints were not respected. 
 
Conclusion: Patients irradiated on small bowel and 
duodenum did not develop severe toxicity although the 
administered doses were above constrains proposed in 
literature. A prolonged follow-up and a larger population are 
needed to confirm the safety of dose-volume constraints 
other than those reported in literature about SBRT and SBRS 
on abdominal area. 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of extra-cranial stereotactic treatment (SBRT) in 
previously irradiated patients. 
 
Material and Methods: In a dose escalation (Phase I) study, 
previously irradiated patients were enrolled in two different 
arms depending on treatment site and previous dose: 1) 
retreatment with previous dose > 60 Gy or retreatment of 
pancreatic and pelvic tumors, 2) retreatment with previous 
dose < 60 Gy. SBRT was delivered in 5 fractions with static 3D 
technique (4 non-coplanar beams) or dynamic arc (VMAT). 
The dose was prescribed at the isocenter. The Planning 
Target Volume (PTV) was defined as the GTV + 5-15 mm 
margin. According to the study arm, the first cohort of 6 
patients received a dose of 20 or 25 Gy, and subsequent 
cohorts of patients received doses up to 40 Gy. The dose 
limiting toxicity (DLT) was defined as any acute and late 
toxicity Grade ≥ 3. The MTD was defined a s the dose level 
with 2/6 or 4/12 DLT. 
 
Results: From September 2004 to December 2014, 51 
patients (M/F: 27/24; median age 65, range 44-87), 
previously irradiated with doses of 30 to 87 Gy (median dose 
50 Gy) were enrolled, after 4-228 months from the first 
treatment (median 11 months). Sixty-six lesions were treated 
(23 primary lesions or relapses, 43 lymphadenopathies) 
mainly from gynecological tumors (30%), followed by 
gastrointestinal tumors (26%) and prostatic tumors (17%). 
Nineteen of the 66 lesions were in the neck or chest, 22 in 
the abdomen and 25 in the pelvis. With a median follow-up of 
19 months (3-104), an overall response rate of 81% (Complete 
Response: 55%, Partial Response: 26%), with only 3% of 
disease progression was recorded. At 40 Gy dose-level, only 1 
patient showed DLT (cutaneous fistula in the sacral region). 
Two-year local control was 75% and 2-year metastasis-free 
survival was 30%. 
 
Conclusion: SBRT treatment in 5 fractions up to a dose of 40 
Gy is well tolerated in previously irradiated patients. This 
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Purpose or Objective: To define the maximum tolerated 
dose (MTD) of stereotactic extracranial radiosurgery 
performed in a single session (SBRS) in different clinical 
settings. 
 
Material and Methods: Based on a Dose Escalation study 
(Phase I), oligometastatic patients were enrolled in 4 
different arms depending on site and treatment purpose: 1) 
liver metastases, 2) lung metastases, 3) lymph node 
metastases or liver or lung metastases with a prolonged local 
control purpose, 4) bone metastases (non-vertebral). Dose 
was prescribed according to the Rosel protocol (V100 >95%, 
V90 >99% and Dmax <140% of the prescription) with dynamic 
